Alkermes plc. Debt Securities, Held-to-maturity, Maturity, without Single Maturity Date, Fair Value
Alkermes plc. (ALKS) had Debt Securities, Held-to-maturity, Maturity, without Single Maturity Date, Fair Value of $3.68 million as of 2017-12-31, per its 10-K filed 2018-02-16.
Discontinued › Notes › Investments › Debt and Equity Securities › Debt Securities, Held-to-Maturity, Maturity › Debt Securities, Held-to-Maturity, Fair Value, Maturity
us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue · last filed 2018-02-16
- 2017-12-31: Debt Securities, Held-to-maturity, Maturity, without Single Maturity Date, Fair Value $3.68M.
- 2016-12-31: Debt Securities, Held-to-maturity, Maturity, without Single Maturity Date, Fair Value $3.38M.
| Period end | Debt Securities, Held-to-maturity, Maturity, without Single Maturity Date, Fair Value |
|---|---|
| 2017-12-31 | $3.68M 10-K · filed 2018-02-16 |
| 2016-12-31 | $3.38M 10-K · filed 2017-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |